Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 11/2019

01-11-2019 | Positron Emission Tomography | Original Article

4′-[methyl-11C]-thiothymidine as a proliferation imaging tracer for detection of colorectal cancer: comparison with 18F-FDG

Authors: Yuko Fukuda, Yuka Yamamoto, Katsuya Mitamura, Ryo Ishikawa, Eisuke Asano, Jun Toyohara, Takashi Norikane, Yoshihiro Nishiyama

Published in: Annals of Nuclear Medicine | Issue 11/2019

Login to get access

Abstract

Objective

The novel radiotracer, 4′-[methyl-11C]-thiothymidine (11C-4DST), was developed based on the DNA incorporation method as a cell proliferation marker. This study investigated the feasibility of 11C-4DST positron emission tomography/computed tomography (PET/CT) for detection of colorectal cancer, as compared with 2-deoxy-2-18F-fluoro-d-glucose (18F-FDG) PET/CT, and to correlate the two radiotracers with proliferative activity.

Methods

A total of 18 patients with newly diagnosed colorectal cancer underwent both 11C-4DST and 18F-FDG PET/CT. Tumor lesions were identified as areas of focally increased uptake, exceeding that of adjacent normal tissue. For semiquantitative analysis, the maximal standardized uptake value (SUVmax) was calculated. Proliferative activity as quantified by the Ki-67 index was estimated in tumor specimens.

Results

In all 18 patients, colorectal cancers were detected by both 11C-4DST and 18F-FDG PET/CT. The median (± SD) SUVmax for 11C-4DST (6.02 ± 2.55) was significantly lower than that for 18F-FDG (13.91 ± 7.62) (P < 0.001). 11C-4DST SUVmax and 18F-FDG SUVmax showed a significant correlation (r = 0.69, P = 0.002). 11C-4DST SUVmax and Ki-67 index were weakly correlated (r = 0.50, P = 0.04). 18F-FDG SUVmax and Ki-67 index were not significantly correlated (r = 0.44, P = 0.06).

Conclusions

Despite a significantly lower uptake of 11C-4DST than that of 18F-FDG, detection of colorectal cancer was also feasible with 11C-4DST PET/CT. 11C-4DST PET/CT might have a role in the noninvasive assessment of proliferation in colorectal cancer.
Literature
1.
Costa A, Silvestrini R, Mochen C, Lequaglie C, Boracchi P, Faranda A, et al. P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer. Br J Cancer. 1996;73:914–9.CrossRefPubMedPubMedCentral
2.
Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305–32.CrossRefPubMed
3.
Kalff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The clinical impact of 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med. 2002;43:492–9.PubMed
4.
Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, et al. Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002;20:388–95.CrossRefPubMed
5.
Yamamoto Y, Kameyama R, Izuishi K, Takebayashi R, Hagiike M, Asakura M, et al. Detection of colorectal cancer using 18F-FLT PET: comparison with 18F-FDG PET. Nucl Med Commun. 2009;30:841–5.CrossRefPubMed
6.
Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut. 2003;52:1602–6.CrossRefPubMedPubMedCentral
7.
Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A, et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:878–83.CrossRefPubMed
8.
Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210–7.PubMed
9.
Toyohara J, Kumata K, Fukushi K, Irie T, Suzuki K. Evaluation of 4′-[methyl-14C] thiothymidine for in vivo DNA synthesis imaging. J Nucl Med. 2006;47:1717–22.PubMed
10.
Toyohara J, Okada M, Toramatsu C, Suzuki K, Irie T. Feasibility studies of 4′-[methyl-11C] thiothymidine as a tumor proliferation imaging agent in mice. Nucl Med Biol. 2008;35:67–74.CrossRefPubMed
11.
Toyohara J, Nariai T, Sakata M, Oda K, Ishii K, Kawabe T, et al. Whole-body distribution and brain tumor imaging with 11C-4DST: a pilot study. J Nucl Med. 2011;52:1322–8.CrossRefPubMed
12.
Minamimoto R, Toyohara J, Seike A, Ito H, Endo H, Morooka M, et al. 4′-[methyl-11C]-thiothymidine PET/CT for proliferation imaging in non-small cell lung cancer. J Nucl Med. 2012;53:199–206.CrossRefPubMed
13.
Tanaka K, Yamamoto Y, Maeda Y, Yamamoto H, Kudomi N, Kawai N, et al. Correlation of 4′-[methyl-11C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with 11C-methionine uptake. Ann Nucl Med. 2016;30:89–96.CrossRefPubMed
14.
Ito K, Yokoyama J, Miyata Y, Toyohara J, Okasaki M, Minamimoto R, et al. Volumetric comparison of positron emission tomography/computed tomography using 4′-[methyl-11C]-thiothymidine with 2-deoxy-2-18F-fluoro-d-glucose in patients with advanced head and neck squamous cell carcinoma. Nucl Med Commun. 2015;36:219–25.CrossRefPubMed
15.
Hoshikawa H, Mori T, Maeda Y, Takahashi S, Ouchi Y, Yamamoto Y, et al. Influence of volumetric 4′-[methyl-11C]-thiothymidine PET/CT parameters for prediction of the clinical outcome of head and neck cancer patients. Ann Nucl Med. 2017;31:63–70.CrossRefPubMed
16.
Minamimoto R, Nakaigawa N, Nagashima Y, Toyohara J, Ueno D, Namura K, et al. Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study. Abdom Radiol. 2016;41:521–30.CrossRef
17.
Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
18.
Plotnik DA, Wu S, Linn GR, Yip FCT, Comandante NL, Krohn KA, et al. In vitro analysis of transport and metabolism of 4′-thiothymidine in human tumor cells. Nucl Med Biol. 2015;42:470–4.CrossRefPubMed
Metadata
Title
4′-[methyl-11C]-thiothymidine as a proliferation imaging tracer for detection of colorectal cancer: comparison with 18F-FDG
Authors
Yuko Fukuda
Yuka Yamamoto
Katsuya Mitamura
Ryo Ishikawa
Eisuke Asano
Jun Toyohara
Takashi Norikane
Yoshihiro Nishiyama
Publication date
01-11-2019
Publisher
Springer Singapore
Published in
Annals of Nuclear Medicine / Issue 11/2019
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-019-01393-2

Other articles of this Issue 11/2019

Annals of Nuclear Medicine 11/2019 Go to the issue

Original Article

Effect of drugs containing glucose on FDG-PET image quality

Original Article

Computer-aided detection of bone metastasis in bone scintigraphy images using parallelepiped classification method

Original Article

A pitfall of white matter reference regions used in [18F] florbetapir PET: a consideration of kinetics

Original Article

18F-FDG PET/CT in the evaluation of cartilaginous bone neoplasms: the added value of tumor grading

Special Article

Manual on the proper use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials

Original Article

Impact of decompressive craniectomy on brain perfusion scintigraphy as an ancillary test for brain death diagnosis